[1]罗仕云,付堂清,肖 童.替雷利珠单抗联合射频消融术治疗中晚期非小细胞肺癌的疗效[J].介入放射学杂志,2025,34(04):393-397.[doi:10.3969/j.issn.1008-794X.2025.04.010]
　LUO Shiyun,FU Tangqing,XIAO Tong..Curative efficacy of tiragolumab combined with radiofrequency ablation for advanced non-small cell lung cancer[J].J Intervent Med,2025,34(04):393-397.[doi:10.3969/j.issn.1008-794X.2025.04.010]
点击复制

替雷利珠单抗联合射频消融术治疗中晚期非小细胞肺癌的疗效()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年04
页码:
393-397
栏目:
临床研究
出版日期:
2025-04-23

文章信息/Info

Title:
Curative efficacy of tiragolumab combined with radiofrequency ablation for advanced non-small cell lung cancer
文章编号:
1008-794X(2025)-004-0393-05
作者:
罗仕云;  付堂清;  肖 童
610041 四川成都 三六三医院胸外科
Author(s):
LUO Shiyun; FU Tangqing; XIAO Tong.
Department of Thoracic Surgery,Sanliusan Hospital,Chengdu,Sichuan Province 610041,China
关键词:
替雷利珠单抗;  CT 引导下射频消融术;  非小细胞肺癌;  免疫功能
分类号:
R730.58
DOI:
10.3969/j.issn.1008-794X.2025.04.010
文献标志码:
B
摘要:
目的 探讨替雷利珠单抗联合射频消融术对中晚期非小细胞肺癌(NSCLC)患者免疫功能的影响。方法 纳入2021年1月至2022年1月三六三医院治疗的中晚期NSCLC患者92例。通过随机数字表法分为两组,每组46例。对照组患者接受CT 引导下射频消融术联合化学治疗,观察组在此基础上加用替雷利珠单抗,21 d为1个周期,两组均治疗4个周期。比较两组患者的临床疗效和不良反应,以及治疗前后两组患者的免疫功能指标、肿瘤标志物、肺功能指标。治疗结束后随访2年,记录患者的无进展生存期和生存率。结果 观察组治疗总有效率高于对照组,且观察组治疗后的免疫功能、肺功能指标比对照组提高,肿瘤标志物水平低于对照组,差异均有统计学意义(P<0.05)。两组患者的不良反应发生率差异无统计学意义(P>0.05)。随访结果显示,观察组的无进展生存期和生存率均比对照组增加,差异有统计学意义(P<0.05)。结论 替雷利珠单抗联合射频消融术能够改善NSCLC患者免疫功能,提高治疗效果和生存率。

参考文献/References:

[1] Abdullah S,Chakraborty R,Kumkar PS,et al.Molecular pathogenesis,organ metastasis,and targeted therapy for non-small-cell lung cancer[J].J Environ Pathol Toxicol Oncol,2024,43:13-38.
[2]Sun Q,Li W,Liu T,et al.Individualized treatment for advanced non-small cell lung cancer:a case report and literature review[J].Front Oncol,2022,12:916681.
[3]Laeseke P,Ng C,Ferko N,et al.Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC:a systematic literature review and meta-analysis[J].Lung Cancer,2023,182:107259.
[4]孙有文,仇志勇,万宝年.磁约束燃烧等离子体物理的现状与展望[J].物理学报,2024,73:189-201.
[5]王小凤,柏 慧,黄国定,等.晚期非小细胞肺癌免疫检查点抑制剂联合立体定向放疗研究进展[J].中华放射肿瘤学杂志,2022,31:298-302.
[6]Song Y,Gao Q,Zhang H,et al.Tislelizumab for relapsed/refractory classical hodgkin lymphoma:3-year follow-up and correlative biomarker analysis[J].Clin Cancer Res,2022,28:1147-1156.
[7]中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40:935-964.
[8]Eisenhauer E,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45:228-247.
[9]Su C,Wu J,Choi E,et al.Overall survival among patients with de novo stage Ⅳ metastatic and distant metastatic recurrent non-small cell lung cancer[J].JAMA Netw Open,2023,6:e2335813.
[10]Zhao C,Wang F,Huang J,et al.The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer[J].Eur J Clin Pharmacol,2021,77:685-695.
[11]洪子强,白向豆,崔百强,等.经皮射频消融与微波消融治疗肺癌有效性及安全性的Meta分析[J].介入放射学杂志,2023,32:341-349.
[12]Benelli N,Brandon I,Hew K.Immune checkpoint inhibitors:a narrative review on PD-1/PD-L1 blockade mechanism,efficacy,and safety profile in treating malignancy[J].Cureus,2024,16:e58138.
[13]Yu T,Liu X,Wu C,et al.Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors[J].Clin Transl Sci,2024,17:e13769.
[14]朱风婷,曾江正,姜靖雯,等.卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究[J].中国药业,2021,30:38-41.
[15]Jiao J,Li W,Shang Y,et al.Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function[J].Pak J Med Sci,2023,39:404-408.
[16]Leung J,Cassimeris L.Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry:roles of depolymerizing kinesins and severing proteins[J].Cancer Biol Ther,2019,20:1337-1347.
[17]Aliyaskarova U,Baiken Y,Renaud F,et al.NEIL3-mediated proteasomal degradation facilitates the repair of cisplatin-induced DNA damage in human cells[J].Sci Rep,2023,13:5174.
[18]Zhang Y,Geng H,Zeng L,et al.Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma[J].Hematol Oncol,2024,42:e3227.
[19]李小雪,张 毅,姚舒洋,等.替雷利珠单抗联合化疗治疗Ⅲb～Ⅳ期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2024,40:335-339.
[20]Yajuk O,Baron M,Toker S,et al.The PD-L1/PD-1 axis blocks neutrophil cytotoxicity in cancer[J].Cells,2021,10:1510.
[21]Li Z,Sun G,Sun G,et al.Various Uses of PD1/PD-L1 inhibitor in oncology:opportunities and challenges[J].Front Oncol,2021,11:771335.
[22]王秀丽,刘 婷,冯钊慧,等.替雷利珠单抗相关药物不良反应文献分析[J].中国医院药学杂志,2022,42:2064-2068.
[23]尹岳松,吴玉佩,张丽娜,等.免疫检查点抑制剂相关血栓栓塞事件文献分析[J].中国新药杂志,2024,33:1514-1520.
(收稿日期:2024-09-23)
(本文编辑:新 宇)

相似文献/References:

[1]梁超,李浩,韩大千,等.支气管动脉灌注化疗栓塞联合替雷利珠单抗治疗晚期非小细胞肺癌的有效性与安全性[J].介入放射学杂志,2025,34(02):148.
　LIANG Chao,LI Hao,HAN Daqian,et al.Efficacy and safety of bronchial arterial chemoembolization combined with tislelizumab for advanced non-small cell lung cancer [J].J Intervent Med,2025,34(04):148.

备注/Memo

备注/Memo:
基金项目: 四川省科研基金资助项目(2022HG034122)
通信作者: 罗仕云 E-mail:18982211363@163.com
更新日期/Last Update: 2025-04-25